Intelerad Acquires PenRad Technologies
What You Should Know: – Today, Intelerad, a leading global provider of enterprise medical imaging solutions, announced its acquisition of PenRad, a software provider for […]
lung cancer
AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer
On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell […]
Aloe Fails to Help Radiation Therapy Skin Burns
What are the effects of aloe on radiation burns caused by cancer treatment and on the cancer itself? “Worldwide attention was drawn to the possible […]
How Effective Is Chemotherapy for Colon, Lung, Breast, and Prostate Cancers?
How effective is chemotherapy for colon, lung, breast, and prostate cancers? “Over the last several decades…medicine has waged a major war against cancer, concentrating on […]
$3.7 Trillion Reasons to Centralize Chronic Disease Management
Ty Vachon M.D., Cofounder at Oatmeal Health 59% of all Americans (194 million) suffer from at least one chronic disease, and almost one in three adults […]
2nd NSCLC Drug Development Summit
The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. The industry is uniting to address […]
BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche
Bristol Myers Squibb is splashing out $4.1 billion to acquire Turning Point Therapeutics, a clinical-stage biotech whose lead drug is currently in pivotal testing as […]
Median Tech debuts AI-focused unit for cancer trial support
Medical imaging specialist Median Technologies has launched a new business unit that will provide decision-making tools – underpinned by artificial intelligence – for sponsors of […]
Giving physicians the power of precision imaging for lung disease
Confocal laser endomicroscopy is an imaging technology that delivers visibility into cellular activity that enables physicians to assess areas of concern in cases where conventional disease […]
Closely watched Roche drug fails a second pivotal test in lung cancer
Roche reported that its drug tiragolumab failed to achieve one of two main goals of a Phase 3 study in non-small cell lung cancer. The […]
Potential of Implementing Polygenic Risk Scores in Healthcare Systems
Dr. George Busby, co-founder and Chief Scientific Officer at Allelica The promise of personalized medicine is a world in which interventions, screening, and therapeutics are […]
COTA Promotes Miruna Sasu to President and CEO
Miruna Sasu, Ph.D., MBA, President & CEO at COTA, Inc. What You Should Know: – COTA, Inc., an oncology real-world data and analytics company, announced […]
Day 3 HIMSS Roundup: Glooko Acquires DIABNEXT, GE Healthcare/AliveCor Integration
Venture Capital, Private Equity, Mergers & Acquisitions (M&A) Activity Glooko Acquires DIABNEXT® to Expand Diabetes Offerings in France Glooko, a leading provider of remote patient […]
FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China
The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights […]
FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China
The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights […]
Sugemalimab plus chemo boosts lung cancer survival, trial reveals
Lung cancer drug sugemalimab has delivered positive results following a phase 3 trial. EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 […]
Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos
Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing […]
Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs
Antibody drug conjugates deliver a targeted strike to tumors, but the toxic payloads of these therapies can still reach healthy tissue. Mythic Therapeutics’ FateControl technology ensures […]
Scotland is world’s first country to greenlight Tagrisso for NSCLC
Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small cell lung cancer (NSCLC), making it the […]
Opdivo and chemotherapy combo increases survival in lung cancer patients
Lung cancer drug Opdivo administered with chemotherapy has been shown to boost survival rates in patients with resectable non-small cell lung cancer (NSCLC). The phase […]
Imagine a world without disease [Sponsored]
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is […]
Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer
Shots: The P-III CANOPY-1 trial evaluates canakinumab (ACZ885) + pembrolizumab + platinum-based doublet CT vs PBO + pembrolizumab + CT in patients with LA or […]
Strike two for Novartis’ lung cancer antibody canakinumab
Expectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 trial in non-small cell lung cancer (NSCLC) […]
Good news for Lilly as sintilimab hits the spot in lung cancer again
Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent’s sintilimab last year, and a new trial […]
Roche scores early adjuvant lung cancer approval for Tecentriq
Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC), giving the drug a lead in early-stage […]
Cáncer sin quimioterapia: una revolución silenciosa
Un número cada vez mayor de pacientes con cáncer, especialmente los de mama y pulmón, se libran del temido tratamiento en favor de otras alternativas.
Cáncer sin quimioterapia: una revolución silenciosa
Un número cada vez mayor de pacientes con cáncer, especialmente los de mama y pulmón, se libran del temido tratamiento en favor de otras alternativas.
Cancer Without Chemotherapy: ‘A Totally Different World’
A growing number of cancer patients, especially those with breast and lung cancers, are being spared the dreaded treatment in favor of other options.
NHS fast tracks access to Amgen’s just-approved KRAS cancer drug
Amgen’s first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement to allow early access while its cost-effectiveness […]
AI ‘could help diagnose lung cancer a year earlier’
An artificial intelligence algorithm was able to detect signs of lung cancer on CT scans a year earlier than with traditional methods, according to a […]
J&J lung cancer initiative will use Optellum’s ‘digital biomarker’ tech
Three years ago, Johnson & Johnson set up a wide-ranging initiative with Boston University to try to improve lung cancer survival rates through prevention and […]
ViewPoints Interview: Q BioMed’s Denis Corin Shares Insights on the Agreement to Serve US Department of Defense and Veterans Affairs
In an interview with PharmaShots, Denis Corin, Chief Executive Officer and Chairman of the Board at Q BioMed share his views on the supply agreement […]
Amgen nabs speedy approval for first-ever KRAS drug sotorasib
After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that inhibits KRAS – a cancer target that […]
Janssen claims FDA okay for would-be Tagrisso rival Rybrevant
Johnson & Johnson’s Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant as a treatment for EGFR-mutated non-small cell […]
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such […]
BMS agrees deal worth up to $1.56bn for Agenus’ TIGIT cancer drug
Bristol-Myers Squibb has paid $200 million, and promised up to $1.36 billion in “biobucks” for exclusive rights to a cancer antibody still in the labs […]
Patients in England get fast access to AZ’s Tagrisso in early lung cancer
The UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early stage lung cancer, with NICE allowing fast […]
Roche’s Tecentriq gets fourth European lung cancer indication
Roche’s cancer immunotherapy Tecentriq has been granted a new use by European regulators, for the first-line treatment of certain patients with metastatic non-small cell lung […]
Non-Small Cell Lung Cancer Drug Development Summit
The Non-Small Cell Lung Cancer (NSCLC) Drug Development Summit is the definitive industry-led forum for drug development in the largest solid tumor indication. This is a strategic conference designed […]
Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate Targeted Therapies for Lung Cancer
Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, […]
Boehringer and MD Anderson extend KRAS cancer collaboration
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations. […]
Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases
That is the title of a paper I just published at Value in Health with Suepattra G. May, Lauren M. Zhao, Katalin Bognar, Yong Yuan, […]
To Advance Health Equity, Put Real-World Cancer Data to Work
Dr. Miller, Medical Director of CancerLinQ LLC Despite decades of scientific progress against cancer, access to treatment remains highly unequal. Some of the reasons — […]
Novartis’ canakinumab falls short in phase 3 lung cancer trial
Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work […]
Merck & Co axes Keytruda lung cancer niche amid FDA crackdown
Merck & Co has voluntarily withdrawn its Keytruda immunotherapy from a lung cancer niche in the US, amid a crackdown by the FDA on drugs […]
How Scientists Shot Down Cancer’s ‘Death Star’
No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening.
How Scientists Shot Down Cancer’s ‘Death Star’
No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening.
How Scientists Shot Down Cancer’s ‘Death Star’
No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening.
NICE backs NHS funding for MSD’s Keytruda combination in lung cancer
NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with pemetrexed and platinum chemotherapy in certain lung […]
EMD Serono targeted therapy gets speedy FDA approval for lung cancer
EMD Serono’s Tepmetko is one of a number of targeted cancer therapies that have passed FDA muster in the past year. The decision sets up […]
AZ/Daiichi Sankyo’s partnership makes progress in lung cancer
AstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as part of their ongoing partnership. Results announced […]
Coconut Oil and the Boost in HDL “Good” Cholesterol
The effects of coconut oil were compared to butter and tallow. Even if virgin coconut oil and other saturated fats raise LDL “bad” cholesterol, isn’t […]
Pandemic ‘pushed lung cancer services back 20 years’, doctors warn
Governments must act to restore the damage done to lung cancer services during the pandemic in order to reduce further avoidable deaths, according to a […]
GSK/Merck & Co’s hopeful bintrafusp alfa fails in key lung cancer trial
GlaxoSmithKline’s big gamble on a cancer drug developed by Germany’s Merck KGaA looks unlikely to pay out, after bintrafusp alfa failed to outperform US-based Merck […]
Scotland backs Roche’s Rozlytrek for ROS1 lung cancer
The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of lung cancer, almost seven months after NICE […]
Arsenic in Infant Rice Cereal
When it comes to rice and rice-based products, pediatric nutrition authorities have recommended that arsenic intake should be as low as possible. “The US Food […]
AZ’s Tagrisso gets new early lung cancer use in US
AstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its use to a group of patients with […]
Amgen files KRAS trailblazer sotorasib with FDA for lung cancer
Amgen has filed its groundbreaking KRAS inhibiting drug sotorasib with the FDA for a group of lung cancer patients with an aggressive form of the […]
Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China
Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications […]
Merck & Co buys cancer biotech VelosBio for $2.75bn
Merck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion in cash. Known as MSD outside North […]
FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancer
The FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung cancer. Results from the phase 3 ADAURA […]
The Role of Meat and Dairy Viruses in Cancer
“Nearly 20% of cancer cases arising worldwide can be linked to infectious agents, including viruses.” Seven viruses are now conclusively tied to human cancers, and, […]
AZ aims to cut cancer clinic visits with new Imfinzi regimen
The FDA is to review data supporting AstraZeneca’s Imfinzi (durvalumab) cancer immunotherapy in a new four-week regimen that will halve the number of required clinic […]
AstraZeneca’s Tagrisso (osimertinib) Receives the US FDA’s BT Designation for the Adjuvant Treatment of Patients with Stage IB-IIIA EGFR-Mutated Lung Cancer
Shots: The BT designation is based on P-III ADAURA trial which involves assessing Tagrisso (80 mg) vs PBO in 682 patients with Stage IB, II, […]
AstraZeneca, Daiichi Sankyo sign $6B deal for antibody-drug conjugate
The companies will share development and commercialization of DS-1062 in solid tumors. They already have a similar deal in place, the $6.9 billion agreement signed […]
AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo
AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal […]
Combating Air Pollution Effects with Food
There is a food that offers the best of both worlds—significantly improving our ability to detox carcinogens like diesel fumes and decreasing inflammation in our […]
Medical Meat Bias
When famed surgeon Michael DeBakey was asked why his studies published back in the 1930s linking smoking and lung cancer were ignored, he had to […]
Using Green Tea to Help Prevent Cancer and Treat Cancer
Tea consumption is associated with a reduced risk of heart disease, stroke, and premature death in general, with each additional cup of green tea a […]
